Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.55 USD | -0.22% | -4.81% | -61.21% |
06-12 | Evotec benefits modestly from research payment | DP |
06-12 | Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-61.21% | 1.59B | - | ||
+40.80% | 55.66B | B- | ||
-8.05% | 38.98B | B | ||
+35.79% | 38.8B | A | ||
-8.98% | 27.32B | C | ||
+10.69% | 26.29B | B- | ||
-16.21% | 20.25B | B | ||
+31.00% | 12.76B | B+ | ||
+28.51% | 12.18B | C+ | ||
-1.67% | 12.12B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- EVT Stock
- EVO Stock
- Ratings Evotec SE